Showing results (871-880 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|September 1, 2005
A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patientsMyrto Trakatelli, Michel Toungouz, Didier Blocklet, et al.Cancer Immunology, Immunotherapy : CII|September 1, 2005
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trialsJunichi Sakamoto, Satoshi Morita, Koji Oba, et al.Cancer Immunology, Immunotherapy : CII|September 1, 2005
Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma modelE Jouanneau, D Poujol, S Gulia, et al.Cancer Immunology, Immunotherapy : CII|September 10, 2005
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCamellia W Adams, David E Allison, Kelly Flagella, et al.Cancer Immunology, Immunotherapy : CII|July 19, 2005
Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4+ T cellsMikiko Fukui, Koji Ueno, Yutaka Suehiro, et al.Cancer Immunology, Immunotherapy : CII|October 11, 2007
Migration deficit in monocyte-macrophages in human ovarian cancerRalph S Freedman, Qing Ma, Ena Wang, et al.Cancer Immunology, Immunotherapy : CII|August 19, 2007
Potential contribution of naïve immune effectors to oral tumor resistance: role in synergistic induction of VEGF, IL-6, and IL-8 secretionAntonia Teruel, Marcela Romero, Nicholas A Cacalano, et al.Cancer Immunology, Immunotherapy : CII|August 11, 2007
Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancerTetsuro Uchida, Shigetoshi Horiguchi, Yuriko Tanaka, et al.Cancer Immunology, Immunotherapy : CII|November 22, 2007
Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culturePeter Dubsky, Hubert Hayden, Monika Sachet, et al.Cancer Immunology, Immunotherapy : CII|November 16, 2007
MYCN as a target for cancer immunotherapyNourredine Himoudi, Mengyong Yan, Antigoni Papanastasiou, et al.Pageof 650